Moreover, the nanoplatform exploits the acidic environment of lysosomes to release EDTA and ICG, achieving a two-pronged strategy: reducing extracellular matrix (ECM) production by down-regulating transforming TGF-β and activating an immune response through the induction of tumor cell immunogenic cell death (ICD). The gene discussed is TGFB1; the disease is neoplasm.